<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607839</url>
  </required_header>
  <id_info>
    <org_study_id>12-5569-B</org_study_id>
    <nct_id>NCT02607839</nct_id>
  </id_info>
  <brief_title>Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans</brief_title>
  <official_title>Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of study is to examine whether raised blood glucose enhances lipid particle
      production independent of effects on gastric emptying and pancreatic/ gastrointestinal
      hormone production.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be performed on healthy, lean, non-diabetic males and females who will
      participate two studies each in random order, 4 to 6 weeks apart. Study A: lipoprotein
      turnover with intravenous infusion of normal saline. Study B: lipoprotein turnover i.v
      infusion of glucose. In both studies, subjects will drink a liquid formula every hour to
      remain in a constant fed state and will be under conditions of pancreatic clamp (with the
      infusion of hormones somatostatin, insulin, glucagon, growth hormone). Subjects will be
      blinded with regard to the treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Production of TRL-apoB48 between treatments</measure>
    <time_frame>10 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Production of TRL-apoB100 between treatments</measure>
    <time_frame>10 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glucose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glucose intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>glucose or normal saline</intervention_name>
    <description>20% glucose solution or normal saline, intravenous infusion</description>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_label>glucose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, aged 18 to 60 years

          2. Body mass index 20 kg/m2 to 27 kg/m2

          3. Hemoglobin above 130g/L

          4. Normal glucose tolerance in response to a 75g, 2-hr OGTT

        Exclusion Criteria:

          1. Subject has a history of hepatitis/hepatic disease that has been active within the
             previous two years.

          2. Any subject with active bleeding, bleeding diathesis, clotting abnormalities or recent
             surgery (within past 1 month)

          3. Any significant active (over the past 12 months) disease of the gastrointestinal,
             pulmonary, neurological, renal (Cr &gt; 1.5 mg/dL), genitourinary, hematological systems,
             or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP &gt;
             100 or systolic &gt; 180).

          4. History of diabetes or OGTT indicative of diabetes or impaired glucose tolerance.

          5. Any history of a MI or clinically significant, active, cardiovascular history
             including a history of arrhythmia's or conduction delays on ECG, unstable angina, or
             decompensated heart failure.

          6. Any laboratory values: AST &gt; 2x ULN; ALT &gt; 2x ULN TSH &gt; 6 mU/l

          7. Current addiction to alcohol or substances of abuse as determined by the investigator.

          8. Mental incapacity, unwillingness or language barrier precluding adequate understanding
             or cooperation

          9. Taking any prescription or non-prescription medications at the time of the study

         10. Having donated blood three months prior to and three months post study procedures

         11. A pregnancy test will be performed 1 to 3 days prior to each study in all female
             subjects. Those who test positive for pregnancy will be excluded.

         12. Known allergy, hypersensitivity or contraindication to receiving study medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tornto General Hospital, UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Gary Lewis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>lipid handling by the gut and liver</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

